PEN - Penumbra, Inc.
NYSE
->
Healthcare
->
Medical Devices
Alameda,
United States
Type: Equity
PEN price evolution
PEN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $288.33 | $223.11 | $167.49 | |
| Short term investments | $51.36 | $90.36 | $121.7 | |
| Net receivables | $176.05 | $200.83 | $191.99 | $201.77 |
| Inventory | $393.41 | $373.8 | $398.37 | $388.02 |
| Total current assets | $891.75 | $943.79 | $935.02 | $915.4 |
| Long term investments | ||||
| Property, plant & equipment | $269.73 | $270.39 | $291.82 | $292.54 |
| Goodwill & intangible assets | $173 | $234.52 | $237.33 | |
| Total noncurrent assets | $590.77 | $644.82 | $640.9 | |
| Total investments | $51.36 | $90.36 | $121.7 | |
| Total assets | $1479.12 | $1534.56 | $1579.85 | $1556.31 |
| Current liabilities | ||||
| Accounts payable | $33.15 | $32.82 | $32.45 | $27.16 |
| Deferred revenue | ||||
| Short long term debt | $14.1 | $13.8 | $13.43 | |
| Total current liabilities | $153.19 | $150.99 | $152.8 | $151.14 |
| Long term debt | $22.25 | $214.72 | $217.63 | $220.91 |
| Total noncurrent liabilities | $222.34 | $223.51 | $226.22 | |
| Total debt | $228.82 | $231.44 | $234.34 | |
| Total liabilities | $374.84 | $373.33 | $376.31 | $377.36 |
| Shareholders' equity | ||||
| Retained earnings | $26.01 | $85.66 | $145.86 | $134.86 |
| Other shareholder equity | -$1.71 | -$5.05 | -$4.84 | -$3.15 |
| Total shareholder equity | $1161.23 | $1203.53 | $1178.94 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $167.49 | $69.86 | $59.38 | $69.67 |
| Short term investments | $121.7 | $118.17 | $195.5 | $195.16 |
| Net receivables | $201.77 | $203.38 | $133.94 | $114.61 |
| Inventory | $388.02 | $334.01 | $263.5 | $219.53 |
| Total current assets | $915.4 | $755.7 | $681.47 | $617.7 |
| Long term investments | ||||
| Property, plant & equipment | $292.54 | $290.97 | $227.09 | $127.43 |
| Goodwill & intangible assets | $237.33 | $247.21 | $257.01 | $19.01 |
| Total noncurrent assets | $640.9 | $615.19 | $562.78 | $205.28 |
| Total investments | $121.7 | $118.17 | $195.5 | $195.16 |
| Total assets | $1556.31 | $1370.89 | $1244.25 | $822.98 |
| Current liabilities | ||||
| Accounts payable | $27.16 | $26.68 | $13.42 | $14.11 |
| Deferred revenue | ||||
| Short long term debt | $13.43 | $11.95 | $9.98 | $6.03 |
| Total current liabilities | $151.14 | $144.93 | $123.2 | $105.93 |
| Long term debt | $220.91 | $24.86 | $163.57 | $71.25 |
| Total noncurrent liabilities | $226.22 | $227.1 | $167.13 | $79.26 |
| Total debt | $234.34 | $235.77 | $173.55 | $77.28 |
| Total liabilities | $377.36 | $372.03 | $290.32 | $185.19 |
| Shareholders' equity | ||||
| Retained earnings | $134.86 | $43.9 | $45.91 | $40.62 |
| Other shareholder equity | -$3.15 | -$4.62 | -$2.63 | $2.54 |
| Total shareholder equity | $1178.94 | $998.86 | $953.93 | $641.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $299.4 | $278.65 | $284.68 | |
| Cost of revenue | $136.57 | $97.52 | $97.69 | |
| Gross Profit | $162.83 | $181.14 | $186.99 | |
| Operating activities | ||||
| Research & development | $24.94 | $24.63 | $21.94 | |
| Selling, general & administrative | $141.9 | $144.41 | $130.02 | |
| Total operating expenses | $243.79 | $169.04 | $151.96 | |
| Operating income | -$80.96 | $12.1 | $35.03 | |
| Income from continuing operations | ||||
| EBIT | -$77.87 | $14.63 | $38.16 | |
| Income tax expense | -$17.67 | $3.62 | -$16.06 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$60.2 | $11 | $54.22 | |
| Income (for common shares) | -$60.2 | $11 | $54.22 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1058.52 | $847.13 | $747.59 | $560.41 |
| Cost of revenue | $375.88 | $311.93 | $272.21 | $222.24 |
| Gross Profit | $682.64 | $535.21 | $475.38 | $338.18 |
| Operating activities | ||||
| Research & development | $84.42 | $79.41 | $104.55 | $90.05 |
| Selling, general & administrative | $506.45 | $449.72 | $378.33 | $287.07 |
| Total operating expenses | $609.09 | $529.13 | $482.88 | $377.12 |
| Operating income | $73.55 | $6.08 | -$7.5 | -$38.94 |
| Income from continuing operations | ||||
| EBIT | $79.65 | $3.89 | -$7.84 | -$34.46 |
| Income tax expense | -$11.3 | $5.89 | -$13.13 | -$18.76 |
| Interest expense | ||||
| Net income | ||||
| Net income | $90.95 | -$2 | $5.28 | -$15.7 |
| Income (for common shares) | $90.95 | -$2 | $5.28 | -$15.7 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$60.2 | $11 | $54.22 | |
| Operating activities | ||||
| Depreciation | $7.65 | $7.52 | $7.04 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.56 | $13.57 | $10.79 | |
| Total cash flows from operations | $22.61 | $38.3 | $36.26 | |
| Investing activities | ||||
| Capital expenditures | -$4.54 | -$5.82 | -$3.65 | |
| Investments | $39.51 | $22.11 | $27.93 | |
| Total cash flows from investing | $88.58 | $34.47 | $18.38 | $24.28 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.92 | $0.24 | $7.37 | |
| Net borrowings | -$0.56 | -$0.55 | -$0.53 | |
| Total cash flows from financing | -$93.07 | $8.27 | -$0.79 | $5.92 |
| Effect of exchange rate | $0.11 | -$0.14 | -$0.26 | $0.27 |
| Change in cash and equivalents | $112.99 | $65.22 | $55.63 | $66.73 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $90.95 | -$2 | $5.28 | -$15.7 |
| Operating activities | ||||
| Depreciation | $27.26 | $24.32 | $16.41 | $12.89 |
| Business acquisitions & disposals | -$0.99 | $2.92 | ||
| Stock-based compensation | $50.52 | $37.38 | $65.76 | $25.54 |
| Total cash flows from operations | $97.33 | -$55.66 | $9.5 | -$33.24 |
| Investing activities | ||||
| Capital expenditures | -$15.21 | -$19.3 | -$21.18 | -$24.76 |
| Investments | $0.63 | $74.09 | -$3.07 | -$76.33 |
| Total cash flows from investing | -$16.08 | $54.79 | -$21.73 | -$104.15 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $20.41 | $21.55 | $18.37 | $151.3 |
| Net borrowings | -$1.98 | -$1.75 | -$1.45 | -$3.42 |
| Total cash flows from financing | $16.2 | $11.62 | $0.84 | $134.92 |
| Effect of exchange rate | $0.17 | -$0.27 | $1.11 | -$0.64 |
| Change in cash and equivalents | $97.63 | $10.48 | -$10.29 | -$3.11 |
News
Fundamentals
| Market cap | $10.57B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 38.36M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.32 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.82 |
| Quick ratio | 3.25 |